Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature - PubMed (original) (raw)

. 2024 Mar 1;79(3):E93-E94.

doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.

Affiliations

Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Jeffrey V Lazarus et al. Hepatology. 2024.

No abstract available

Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
Emanuele E, Minoretti P. Emanuele E, et al. Hepatology. 2024 Jan 1;79(1):E4. doi: 10.1097/HEP.0000000000000586. Epub 2023 Aug 30. Hepatology. 2024. PMID: 37651223 No abstract available.

1. Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–52.
1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86.
1. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023. published online ahead of print, 2023 Aug 2.
1. Ratziu V, Boursier J. AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2023. published online ahead of print, 2023 Aug 3.
1. Morse DF, Sandhu S, Mulligan K, Tierney S, Polley M, Chiva Giurca B, et al. Global developments in social prescribing. BMJ Glob Health. 2022;7:e008524.